Detalhe da pesquisa
1.
Differential inhibition of T-cell receptor and STAT5 signaling pathways determines the immunomodulatory effects of dasatinib in chronic phase chronic myeloid leukemia.
Haematologica
; 108(6): 1555-1566, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700403